



UNITED STATE DEPARTMENT OF COMMERCE United States Patent and Trademark Offic

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.	
09/715,2	49 11/17	/00 PIPPIG	S	4-31192/CIP	
		コ		EXAMINER	
		HM12/0615			
THOMAS HOXIE			GA	GANSHERDEF I	
NOVARTIS	CORPORATIO	ART UNIT	PAPER NUMBER		
564 MORR	ND TRADEMAI IS AVENUE J 07901-10:		16 DATE MAILEI	36	
				06/15/01	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

•	Application No.	Applicant(s)				
Office Action Summary	09/715,249	PIPPIG ET AL.				
•	Examiner	Art Unit				
	Lisa Gansheroff	1636				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36 (a). In no event, however, may a reply be tir y within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from	nely filed s will be considered timely. the mailing date of this communication. D. (35 U.S.C. & 133)				
1) Responsive to communication(s) filed on	· •					
_	is action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-30</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) ☐ Claim(s) is/are objected to.						
8) Claims 1-30 are subject to restriction and/or e	election requirement.					
Application Papers						
9) The specification is objected to by the Examine	er.					
10) The drawing(s) filed on is/are objected t						
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. § 119						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
_	s have been received					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).						
Attachment(s)						
 15) Notice of References Cited (PTO-892) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 	19) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)				

Application/Control Number: 09/715,249

Art Unit: 1636

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-3 and 5-29, drawn to methods for identifying genetically modified mammalian cells, for immunoselection of transduced mammalian cells, and for identifying mammalian cells expressing a protein of interest, with respect to a nucleic acid encoding a modified EGFR family member, classified in class 435, subclass 6.
- II. Claims 1, 2, and 4-29, drawn to methods for identifying genetically modified mammalian cells, for immunoselection of transduced mammalian cells, and for identifying mammalian cells expressing a protein of interest, with respect to a nucleic acid encoding a modified MuSK-R family member, classified in class 436, subclass 6.
- III. Claim 30, drawn to a mutated MuSK-R family member, classified in class 530, subclass 350.

The inventions are distinct, each from the other because of the following reasons:

Inventions I, II, and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are different methods and a product that is not used in the methods.

Application/Control Number: 09/715,249

Art Unit: 1636

Inventions I and II each comprise a step not present in or required for the other method. For example, the method of Invention I requires introducing into a cell a nucleic acid encoding a mutated/modified EGFR, while the method of Invention II requires introducing into a cell a nucleic acid encoding a mutated/modified MuSK-R. The product of Invention III, which is a receptor, is not used in the methods; the method of Invention I is not related to MuSK-R, and the method of Invention II required a nucleic acid encoding a MuSK-R receptor, but not the receptor, which is a protein and thus distinct from a nucleic acid.

Claims 1, 2, and 5-29 are generic to Groups I and II and will be examined only to the extent that they read on the elected Group.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, and because examination of the groups together would be a burden, restriction for examination purposes as indicated is proper.

A telephone call was made to Geoffrey Karny on 01 June 2001 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

Art Unit: 1636

currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lisa J. Gansheroff whose telephone number is (703) 605-1203. The examiner can normally be reached 9 AM - 5 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader can be reached at (703) 308-0447. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242 for regular communications. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the patent analyst Dianiece Jacobs whose telephone number is (703) 305-3388 or to the receptionist whose telephone number is (703) 308-0196.

LG June 1, 2001

> JAMES KETTER PRIMARY EXAMINER